Author: Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Xia, Limin
Title: Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? Cord-id: hs62brjp Document date: 2020_10_26
ID: hs62brjp
Snippet: The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 p
Document: The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 patients. Inhibiting CRS by agents suppressing IL-6 may relieve symptoms, shorten the hospital stay and reduce the need for oxygen therapy. Although evidence from randomized, double-blinded clinical trials is still lacking, the IL-6R inhibitor tocilizumab (TCZ) has shown some clinical benefits in the treatment of severe COVID-19 patients and have been included in clinical guidelines. In this review, we focused on the possible mechanisms of TCZ in the treatment of CRS and highlighted some significant considerations in the use of TCZ to treat COVID-19 patients.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and administration dosage: 1
- acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and admission compare: 1
- acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
- acute ards respiratory distress syndrome and long course: 1, 2, 3
- acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- acute ards respiratory distress syndrome and lung alveolar epithelial cell: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute ards respiratory distress syndrome and lung lesion: 1
- acute ards respiratory distress syndrome and lymph node: 1, 2
- acute ards respiratory distress syndrome and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and macrophage inflammatory alpha: 1, 2
- acute ards respiratory distress syndrome and macrophage lymphocyte: 1, 2
- acute ards respiratory distress syndrome and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute ards respiratory distress syndrome develop and adaptive immune system: 1
- acute ards respiratory distress syndrome develop and administration route: 1
- acute ards respiratory distress syndrome develop and long course: 1
- acute ards respiratory distress syndrome develop and lung damage: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome develop and machine learning: 1
Co phrase search for related documents, hyperlinks ordered by date